CN1763196A - 基因突变类型及基因测序方法 - Google Patents
基因突变类型及基因测序方法 Download PDFInfo
- Publication number
- CN1763196A CN1763196A CN 200510098513 CN200510098513A CN1763196A CN 1763196 A CN1763196 A CN 1763196A CN 200510098513 CN200510098513 CN 200510098513 CN 200510098513 A CN200510098513 A CN 200510098513A CN 1763196 A CN1763196 A CN 1763196A
- Authority
- CN
- China
- Prior art keywords
- gene
- cadasil
- exon
- exon4
- codon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 93
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 65
- 238000012163 sequencing technique Methods 0.000 title claims abstract description 27
- 208000010482 CADASIL Diseases 0.000 claims abstract description 116
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims abstract description 116
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 claims abstract description 114
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 claims abstract description 114
- 108020004705 Codon Proteins 0.000 claims abstract description 63
- 108020004414 DNA Proteins 0.000 claims abstract description 62
- 238000012408 PCR amplification Methods 0.000 claims abstract description 45
- 238000001514 detection method Methods 0.000 claims abstract description 31
- 108700024394 Exon Proteins 0.000 claims abstract description 16
- 238000004458 analytical method Methods 0.000 claims abstract description 10
- 238000005516 engineering process Methods 0.000 claims abstract description 10
- 239000002773 nucleotide Substances 0.000 claims abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 50
- 230000008859 change Effects 0.000 claims description 33
- 238000011144 upstream manufacturing Methods 0.000 claims description 25
- 102000001760 Notch3 Receptor Human genes 0.000 claims description 24
- 108010029756 Notch3 Receptor Proteins 0.000 claims description 24
- 101150103623 NOTCH3 gene Proteins 0.000 claims description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 13
- 101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 claims description 10
- 238000013461 design Methods 0.000 claims description 8
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 5
- 230000035772 mutation Effects 0.000 abstract description 18
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 201000010099 disease Diseases 0.000 description 21
- 239000004475 Arginine Substances 0.000 description 20
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 20
- 239000000872 buffer Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000001717 pathogenic effect Effects 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000000869 mutational effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 102000005650 Notch Receptors Human genes 0.000 description 5
- 108010070047 Notch Receptors Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000035606 childbirth Effects 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000002831 pharmacologic agent Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 102000015094 Paraproteins Human genes 0.000 description 3
- 108010064255 Paraproteins Proteins 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 208000021090 palsy Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- 101100074828 Caenorhabditis elegans lin-12 gene Proteins 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000008004 cell lysis buffer Substances 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- -1 repeats Chemical group 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- 101150096316 5 gene Proteins 0.000 description 1
- 239000004956 Amodel Substances 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 101150060155 Dcc gene Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 238000012220 PCR site-directed mutagenesis Methods 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000003932 Transgelin Human genes 0.000 description 1
- 108090000333 Transgelin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 102220248707 rs1555729554 Human genes 0.000 description 1
- 102200064378 rs1555729604 Human genes 0.000 description 1
- 102200064268 rs28933696 Human genes 0.000 description 1
- 102200064269 rs28933697 Human genes 0.000 description 1
- 102220105426 rs879254514 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
患者 | 年龄 | 血压 | 血糖 | 血脂 | 偏头痛 | 卒中 | 痴呆 | 病理 | 影像 | 突变 |
家系1IIaIIbIIcIIfIIIaIIIbIIIcIIIgIIIm家系2IbIIbIIfIIjIIiIImIIIbIIIfIIIgIIIh家系3IIaIIg家系4A | 5249死亡死亡3836353635死亡666463死亡6240343843393434 | NNNNNNNNNNNNNNNNNNNNN不详 | NNNNNNNNNNNNNNNNNNNNN不详 | NNNNNNNNNNNNNNNNNNNNN不详 | -+--+--++------------不详 | -++++--+++++++++--++-不详 | -+++-----++++++----+-不详 | ND+NDND+NDNDNDNDNDNDNDNDND+NDNDNDNDNDND不详 | ND+NDND+NDND++ND++++++-+++ND不详 | -+NDND+-++NDNDND+ND++ND-+ND+-+ |
含外显子 | 柱温 | Buffer A% | Buffer B% |
Exon2Exon3Exon4Exon5Exon6Exon7Exon8Exon9Exon10Exon11Exon12Exon13Exon14Exon15Exon16Exon17Exon18Exon19Exon20Exon21Exon22Exon23 | 65℃66℃66℃64℃64℃66℃65℃63℃67℃64℃63℃64℃64℃63℃62℃65℃66℃65℃65℃61℃65℃65℃ | 45494346434343474942454243434243474648464448 | 55515754575757535158555857575857535452545652 |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510098513 CN1763196B (zh) | 2004-09-13 | 2005-08-31 | 基因突变类型及基因测序方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410074717.7 | 2004-09-13 | ||
CN200410074717 | 2004-09-13 | ||
CN 200510098513 CN1763196B (zh) | 2004-09-13 | 2005-08-31 | 基因突变类型及基因测序方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1763196A true CN1763196A (zh) | 2006-04-26 |
CN1763196B CN1763196B (zh) | 2010-09-08 |
Family
ID=36747517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510098513 Expired - Fee Related CN1763196B (zh) | 2004-09-13 | 2005-08-31 | 基因突变类型及基因测序方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1763196B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101570798B (zh) * | 2009-03-20 | 2011-11-16 | 曹际娟 | 水产品中3种食源性病毒检测试剂盒及检测方法 |
CN105063216A (zh) * | 2015-08-19 | 2015-11-18 | 济南市儿童医院 | 用于检测表皮生长因子基因突变的引物及试剂盒 |
CN105331614A (zh) * | 2015-11-27 | 2016-02-17 | 首都医科大学宣武医院 | 检测cadasil致病基因突变的方法,及其引物、试剂盒 |
CN106148504A (zh) * | 2015-04-23 | 2016-11-23 | 上海交通大学医学院附属第九人民医院 | 检测显性遗传性脑动脉病相关基因的引物及试剂盒和用途 |
CN108707628A (zh) * | 2018-05-28 | 2018-10-26 | 上海海洋大学 | 斑马鱼notch2基因突变体的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2751986B1 (fr) * | 1996-08-01 | 1998-12-31 | Inst Nat Sante Rech Med | Gene implique dans le cadasil, methode de diagnostic et application therapeutique |
-
2005
- 2005-08-31 CN CN 200510098513 patent/CN1763196B/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101570798B (zh) * | 2009-03-20 | 2011-11-16 | 曹际娟 | 水产品中3种食源性病毒检测试剂盒及检测方法 |
CN106148504A (zh) * | 2015-04-23 | 2016-11-23 | 上海交通大学医学院附属第九人民医院 | 检测显性遗传性脑动脉病相关基因的引物及试剂盒和用途 |
CN105063216A (zh) * | 2015-08-19 | 2015-11-18 | 济南市儿童医院 | 用于检测表皮生长因子基因突变的引物及试剂盒 |
CN105331614A (zh) * | 2015-11-27 | 2016-02-17 | 首都医科大学宣武医院 | 检测cadasil致病基因突变的方法,及其引物、试剂盒 |
CN108707628A (zh) * | 2018-05-28 | 2018-10-26 | 上海海洋大学 | 斑马鱼notch2基因突变体的制备方法 |
CN108707628B (zh) * | 2018-05-28 | 2021-11-23 | 上海海洋大学 | 斑马鱼notch2基因突变体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1763196B (zh) | 2010-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1198166A (zh) | 检测牙周病的遗传素因 | |
CN102242212B (zh) | 一种肥厚型心肌病基因分型方法及检测试剂盒 | |
CN1763196A (zh) | 基因突变类型及基因测序方法 | |
CN112226440B (zh) | 一种遗传性原发***的致病突变及其检测试剂 | |
CN1413219A (zh) | Rhd阴性基因座的分子结构 | |
CN1357636A (zh) | CpG岛甲基化检测试剂盒及其应用 | |
CN111705144B (zh) | 一个与猪背膘厚关联的znf2基因内sine转座子多态分子标记及其检测方法 | |
CN1260369C (zh) | 视黄醇结合蛋白4作为每窝产仔数的基因标记 | |
CN110257505B (zh) | 一种非缺失型α地中海贫血点突变快速检测试剂盒及检测方法 | |
CN114317550A (zh) | 一种编码mitf基因突变体的核酸及其应用 | |
CN1869224A (zh) | 基因突变类型及基因测序方法 | |
CN110734969A (zh) | 一种用于检测基因creb1单核苷酸多态性的pcr-rflp方法 | |
Tarzjani et al. | Genetic study of the NOTCH3 gene in CADASIL patients | |
CN114381513B (zh) | 一种与x连锁淋巴增生症相关的生物标志物及其应用 | |
CN110819701A (zh) | 用于荧光定量pcr检测cyp2d6基因多态性的方法 | |
CN101029337A (zh) | 多态性位点基因型预测5-羟色胺再摄取抑制剂类药物作用效果的用途和方法 | |
CN1699595A (zh) | 检测与人类遗传性耳聋相关的wfs1基因突变的方法 | |
CN103160575B (zh) | SAA1β/β纯合子基因型在肝硬化预后诊断及肝硬化诊断中的应用 | |
CN1291038C (zh) | 一种21号染色体数目的快速检测方法 | |
CN100342032C (zh) | 精神***症易感基因检测方法及易感基因和用途 | |
JP5071998B2 (ja) | 本態性高血圧症の判定方法 | |
CN1202205A (zh) | 冠痉挛相关性疾病的诊断 | |
CN1548552A (zh) | 精神***症易感基因检测方法及易感基因和用途 | |
CN1786188A (zh) | 检测载脂蛋白e基因型的方法和试剂盒 | |
CN1737163A (zh) | 快速检测it15基因cag重复序列动态突变的引物及方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20060426 Assignee: BEIJING LAWKE HEALTH LABORATORY CENTER CO.,LTD. Assignor: XUANWU HOSPITAL CAPITAL MEDICAL University Contract record no.: 2012110000156 Denomination of invention: Gene mutation type and gene sequencing method Granted publication date: 20100908 License type: Exclusive License Record date: 20121016 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100908 Termination date: 20190831 |